BioNTech Results Presentation Deck

Multi-platform Strategy | Technology Agnostic Innovation Engine RIBOLYSINS Precision Antibacterials (Phagomed) INDIVIDUALIZED mRNA CANCER 8 ● VACCINES iNeST INFECTIOUS DISEASES VACCINES Prophylactic vaccines internal technology acquisition collaboration digital & Al capability Therapeutic vaccines OFF-THE-SHELF mRNA CANCER VACCINES Fix Vac mRNA TECHNOLOGY ARTIFICIAL INTELLIGENCE mRNA Drug Design Early SARS-CoV-2 variant detection *mRNA encoded cancer-targeting antibodies and Cytokines RIBOLOGICALS* RiboCytokines RiboMabs ● ● Strengthening platform with collaborations and strategic M&A ● CARVac mRNA Vaccine boosted CAR-T cells PERSONALIZED TCR THERAPY KITE Asset Acquisition MULTI-TARGET TCR RESEARCH COLLABORATION (Medigene) CELL & GENE THERAPIES INDIVIDUALIZED NEOANTIGEN T CELL THERAPY mRNA ENCODED HUMABODIES (Crescendo) SOLID TUMOR CAR-T • Ideal CAR-T cell targets NEXT GEN IMMUNO- MODULATORS Bispecific antibodies ANTIBODIES SMALL MOLECULES TARGETED CANCER THERAPIES SELECTIVE TLR-7 ANTAGONISM BIONTECH

View entire presentation